ALK releases its annual report 2014 Copenhagen, 20

Copenhagen, 2015-02-09 08:00 CET (GLOBE NEWSWIRE) --  

ALK ( ALKB:DC / OMX: ALK B / AKABY / AKBLF) achieved one of its best-ever results in 2014. Total revenue, including partner income, was DKK 2,433 million (2,244) and EBITDA before special items amounted to DKK 453 million (258). 

2014 also saw important progress towards ALK’s goal of globalising its SLIT-tablet portfolio: 

In North America, Merck launched the first two SLIT-tablets, GRASTEK ^® and RAGWITEK ^® and initiated the final stage of clinical development for the SLIT-tablet for house dust mite (HDM) allergy. In Japan, Torii advanced the development of the SLIT-tablet for Japanese cedar pollen allergy to the final stage of clinical development and submitted its own registration application for the SLIT-tablet for HDM allergy. In Europe, ALK submitted a registration application for its most important product, the SLIT-tablet for HDM allergic rhinitis and allergic asthma. Moreover, ALK has entered into a strategic partnership with Abbott for Russia and a collaboration with Eddingpharm in China. 

The Board of Directors proposes a dividend of DKK 5 per share to the annual general meeting. 

See page 4 in the attached annual report for highlights of Q4 and full-year 2014 and a summary of the 2015 outlook. 

Audio cast
Today, ALK hosts a meeting for analysts and institutional investors at 12.30 p.m. (CET) at which Management will review the financial results, the outlook and answer questions. The meeting will be audio cast on www.alk-abello.com/investor . 

Participants in the audio cast are kindly requested to call in before 12.25 p.m. (CET). Danish participants should dial in on tel. +45 7025 2300 or +45 7025 6700 and international participants should dial in on tel. +44 208 817 9311. Please use the following Audio Passcode: 8181 5130. The audio cast is available live on our website, where the related presentation will be available shortly before the meeting begins. 

ALK-Abelló A/S  

For further information please contact :
Jens Bager, President and CEO, tel. +45 4574 7576
Investor Relations : Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Press : Martin Barlebo, tel. +45 4574 7901, mobile +45 2064 1143